FDAnews Device Daily Bulletin

ANTARES PHARMA REPORTS FOURTH QUARTER AND YEAR END 2005 FINANCIAL RESULTS

March 22, 2006
A A

Antares Pharma, Inc. today announced that total revenues for the quarter ended December 31, 2005 increased 3% to approximately $734,000 from approximately $716,000 for the same quarter in 2004. The gross margin percentage also increased in the fourth quarter of 2005 to 64% from 50% in the comparable quarter of 2004 as the mix of revenues changed and more royalties, with minimal costs, were reported in 2005. Total operating expenses decreased approximately $546,000 or 18% to $2.4 million in the fourth quarter of 2005 from $3.0 million in the same period of 2004 due to general and administrative cost controls. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060321005224&newsLang=en)